Join us in making lorlatinib accessible

ALK Positive Canada is rallying support from patients, caregivers, families, and friends across the country to advocate for fair and equitable access to lorlatinib. This targeted therapy is vital for ALK-positive lung cancer patients who need second-line or beyond treatment. While public health plans currently cover lorlatinib as a first-line therapy, it is not covered for later lines of treatment where an increasing number of patients require access to it.

Please add your name below to show your support.
It takes 30 seconds and no login is required. If you have any questions, send us a message.

If you are a lung cancer clinician, show your support using our clinician petition here.